Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease

Reid, R. T.; Sabbagh, M. N.; Thal, L. J.
September 2001
Journal of Neural Transmission;Sep2001, Vol. 108 Issue 8/9, p1043
Academic Journal
Summary. We wished to determine the influence of the apolipoprotein E (Apo-E) genotype on the loss of high affinity nicotinic acetylcholine receptor (nAChR) binding in Alzheimer's disease (AD). The interaction between ε4 allele gene dose and cholinergic loss in AD remains controversial. We have demonstrated that nicotinic binding is significantly lost in AD. Tissue from the midfrontal (MF) cortex of 7 subjects with no ε4 allele copies (ε-/ε-) (mean death age 75.1 ± 10.4 years) was compared to MF cortex of 14 subjects heterozygous for the ε4 allele (ε4/ε-) (mean death age 81.4 ± 7.3 years) and MF cortex of 10 subjects homozygous for the ε4 allele (ε4/ε4) (mean death age 79.6 ± 5.0 years). All subjects were autopsy confirmed AD (using NIA and CERAD criteria) and met NINCDS-ADRDA clinical criteria for probable or possible AD. Nicotine AChR binding was assayed using the high affinity nicotinic agonist 3H-epibatidine ([3H]-Epi). Apo-E genotype was determined in blood samples or in post-mortem tissue. The mean age at death was not significantly different among the groups (p = 0.19). There was no difference in mean [3H]-Epi total binding among the three groups (6.7 ± 4.6, 6.1 ± 2.4, and 6.0 ± 1.0 fmol/mg protein for ε-/ε-, ε4/ε-, and ε4/ε4 respectively. We conclude that the presence or absence of the Apo-E4 genotype does not influence the loss of high affinity nAChR in AD.


Related Articles

  • Brain MRI, Apoliprotein E Genotype, and Plasma Homocysteine in American Indian Alzheimer Disease Patients and Indian Controls. Weiner, Myron F.; De la Plata, Carlos Marquez; Fields, B.A. Julie; Womack, Kyle B.; Rosenberg, Roger N.; Yun-Hua Gong; Bao-Xi Qu; Diaz-Arrastia, Ramon; Hynan, Linda S. // Current Alzheimer Research;Jan2009, Vol. 6 Issue 1, p52 

    We obtained brain MRIs, plasma homocysteine levels and apolipoprotein E genotyping for 11 American Indian Alzheimer disease (AD) subjects and 10 Indian controls. We calculated white matter hyperintensity volume (WMHV), whole brain volume (WBV), and ratio of white matter hyperintensity volume to...

  • The effect of the apolipoprotein E gene polymorphisms and haplotypes on behavioural and psychological symptoms in probable Alzheimer's disease. A. I. Pritchard; Harris, J.; Pritchard, C. W.; Coates, J.; Haque, S.; Holder, R.; Bentham, P.; Lendon, C. I. // Journal of Neurology, Neurosurgery & Psychiatry;Feb2007, Vol. 78 Issue 2, p123 

    Background: Patients with Alzheimer's disease and dementia commonly suffer from behavioural and psychological symptoms of dementia (BPSD). A genetic component to BPSD development in Alzheimer's disease has been demonstrated. Several studies have investigated whether the exon 4 ϵ2/ϵ3/ϵ4...

  • Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease. Van Dam, Debby; Coen, Katrien; De Deyn, Peter Paul // Psychopharmacology;Mar2008, Vol. 197 Issue 1, p37 

    The interest for acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease has been greatly renewed owing to the discovery of a broad range of additional cholinergic and non-cholinergic effects, exploitable to maximize the efficacy of these drugs beyond merely improving...

  • Interaction of ATF4 with APOE Promoter -491 Polymorphic Site and Its Functional Significance. Hua Geng; Li-Yun Liang; Ting Li; Kam-Bo Wong; Yuan-Yuan Ho // Diabetes;Jun2007 Supplement 1, Vol. 56, pA517 

    Apolipoprotein E (apoE) is a lipid transport protein present in both peripheral tissues and central nervous system. In addition to the well known polymorphic coding alleles ε2, ε3 and ε4, APOE promoter single nucleotide polymorphisms (SNPs) may also modify the susceptibilities to human...

  • Neurodegeneration in a Drosophila Model for the Function of TMCC2, an Amyloid Protein Precursor-Interacting and Apolipoprotein E-Binding Protein. Hopkins, Paul C. R. // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    We previously identified TMCC2 as a protein that interacted differentially with normal versus Alzheimer's disease-risk forms of both apolipoprotein E (apoE) and the amyloid protein precursor (APP). We hypothesized that disrupted function of TMCC2 would affect neurodegeneration. To test this...

  • APOE...-4: The impact of race and ethnicity on Alzheimer's risk. Pinkowish, Mary Desmond // Patient Care;5/15/1998, Vol. 32 Issue 9, p221 

    Presents a study which examined the association between Alzheimer's disease (AD) and apolipoprotein E e4 (APOEe-4) risk in patients of different ethnic groups. Information on the APOEe-4 allele; Details on the methods and participants used in this study; Findings of the study on the risk of AD...

  • Apolipoprotein E and Presenilin-1 Allelic Variation and Alzheimer's Disease in India. Chandak, G.R.; Sridevi, M. Uma; Vas, C.J.; Panikker, D.M.; Singh, L. // Human Biology;Oct2002, Vol. 74 Issue 5, p683 

    Investigates the prevalence of alzheimer's disease (AD) among persons living in the suburbs of Mumbai, Western India. Association of AD with apolipoprotein E allele at apolipoprotein E gene; Accounts on the risk factors of AD; Clinical manifestations of AD.

  • APOE genotype predicts when ? not whether ? one is predisposed to develop Alzheimer disease. Meyer, Marion R; Tschanz, JoAnn T; Norton, Maria C; Welsh-Bohmer, Kathleen A; Steffens, David C; Wyse, Bonita W; Breitner, John C S // Nature Genetics;Aug98, Vol. 19 Issue 4, p321 

    Studies the occurrence of Alzheimer's disease (AD) in relation to apolipoprotein E (APOE) genotype. Identification of APOE alleles; Clinical assessment for cognitive dysfunction in AD patients; Disease-free survival by age for APOE genotypes.

  • Alzheimer disease ? when and why? Price, Donald L; Sisodia, Sangram S; Borchelt, David R // Nature Genetics;Aug98, Vol. 19 Issue 4, p314 

    Studies the medical and genetic aspects of Alzheimer's disease (AD). Relationship between risk factors, clinical signs and pathogenic mechanisms in AD patients; Prevalence of apolipoprotein E in individuals with AD; Autosomal dominant inheritance patterns of AD; Genes associated with AD.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics